Tag - DFFN

Markets

HCW cuts Diffusion Pharma to neutral; removes price target

H.C. Wainwright downgraded Diffusion Pharmaceuticals (NASDAQ:DFFN) to “neutral” from “buy” without a price target after the company on Nov. 12 announced that it is not moving forward with its two key clinical programs...

November 17, 2020

Markets

HCW cuts Diffusion Pharma PT to $3.50 on dilution

H.C. Wainwright lowered its price target for Diffusion Pharmaceuticals (NASDAQ:DFFN) to $3.50 from $10, reflecting dilution from two recent financings. The stock closed at 41 cents on Dec. 17. Analyst Swayampakula...

December 18, 2019

Feature

Diffusion Pharma readies pivotal hypoxic GBM trial

By Len Zehr Diffusion Pharmaceuticals (NASDAQ:DFFN) expects to begin before the end of 2017 a pivotal clinical trial with its trans sodium crocetinate (TSC) lead compound to re-oxygenate oxygen-deprived tissue in...

October 3, 2017

Tag - DFFN

HCW cuts Diffusion Pharma to neutral; removes price target

HCW cuts Diffusion Pharma PT to $3.50 on dilution

Diffusion Pharma readies pivotal hypoxic GBM trial

General

More